1/16/2023 7:07:43 AM
Kazia Therapeutics Announces Placement Of KZA Shares In Australia At A$0.11/Shr To Raise About A$4.5 Mln
8/5/2022 8:46:15 AM
Kazia Reports Promising Interim Data From Phase I Trial Of Paxalisib-radiotherapy In Brain Metastases Treatment
7/6/2022 7:15:00 AM
FDA Awards Rare Pediatric Disease Designation To Kazia's Paxalisib For Treatment Of Atypical Rhabdoid/teratoid Tumors
6/17/2022 8:03:26 AM
Kazia Therapeutics : FDA Awards Orphan Drug Designation To Paxalisib For Rare Form Of Childhood Brain Cancer
6/7/2022 7:16:36 AM
Kazia Therapeutics Says Phase 2 Study Of Paxalisib In Brain Metastases Advanced To Expansion Stage In Breast Cancer
6/3/2022 7:06:18 AM
Kazia Therapeutics Presents Positive Final Data From Phase II Study Of Paxalisib In Newly Diagnosed Glioblastoma
12/13/2021 11:28:40 AM
Kazia Therapeutics Appoints Karen Krumeich As CFO
11/15/2021 11:05:13 AM
Kazia Therapeutics Appoints John Friend As Chief Medical Officer
6/30/2021 10:02:24 AM
Kazia Updates On Paxalisib And EVT801 Clinical Programs
6/15/2021 10:04:09 AM
Kazia Collaborates With Cornell University For Phase II Study Using Paxalisib-Ketogenic Diet For Glioblastoma
6/7/2021 8:29:01 AM
Kazia Therapeutics Enrols First Patient In Phase II Study Of Paxalisib In Primary CNS Lymphoma
4/19/2021 5:39:51 AM
Evotec Grants Kazia Worldwide License To Develop, Manufacture, And Commercialise EVT801